Logo

Human Metabolome Technologies Signs Biomarker Deal with Mitsubishi Pharma

Feb 17, 2005

NEW YORK, Feb. 17 (GenomeWeb News) - Human Metabolome Technologies of Yamagata, Japan, yesterday announced a biomarker research collaboration with Mitsubishi Pharma.

 

Under the terms of the agreement, HMT will search for biomarkers for the early detection of drug-induced phospholipidosis using its metabolomics tools, which include capillary-electrophoresis and mass spectrometry technology for small-molecule separation and detection.

 

Financial details of the agreement were not disclosed.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.